Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2023-03-14 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
关于为公司全资子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the provision of a guarantee by the company for its wholly-owned subsidiary. It details the guarantee amount, the terms, the necessity and reasonableness of the guarantee, and references prior board and shareholder approvals. The document is a formal disclosure of a specific corporate action (providing a guarantee) rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather focuses on a specific financing-related guarantee event. This fits the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes. The document length is 2598 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2023-03-14 Chinese
关于公司股东国有股权无偿划转完成过户登记的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the completion of a share transfer registration involving state-owned shares between shareholders of the company. It details the transfer of shares from one state-owned entity to its wholly-owned subsidiary and the resulting shareholding percentages. There is no financial data, no mention of a report being attached or published, and no indication of a meeting or voting results. The content is about a change in shareholding structure but not a major shareholding notification crossing thresholds, rather an internal transfer within related parties. This fits best under Regulatory Filings (RNS) as a general regulatory announcement about shareholding changes that do not meet the criteria for other more specific categories.
2023-03-13 Chinese
关于募集资金临时补充流动资金归还的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (615 characters) regarding the return of temporarily used raised funds to the dedicated account. It references a previous announcement about the use of idle raised funds to supplement working capital and confirms the full repayment within the approved period. There are no financial statements or detailed financial data presented, only a status update on the use and return of raised capital. This fits the category of a Capital/Financing Update (CAP) as it relates to the company's fundraising and capital usage activities.
2023-03-09 Chinese
关于使用部分闲置募集资金购买的理财产品到期赎回并继续进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 启迪药业集团股份公司 regarding the use of idle raised funds to purchase and redeem financial products, specifically structured deposits. It details the amounts, dates, risk control measures, and approvals by the board and shareholders. The document is relatively short (3067 characters) and primarily serves as an update on the company's cash management activities involving raised funds. It does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or a proxy statement. The content fits best as a Capital/Financing Update (CAP) because it relates to the company's use of capital raised through fundraising and its management of those funds through financial products. Therefore, the classification is CAP with high confidence.
2023-02-15 Chinese
2022年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2022 annual performance forecast (业绩预告) from 启迪药业集团股份公司, covering the period from January 1, 2022 to December 31, 2022. It provides estimated financial results including net profit and earnings per share, with a clear statement that the data is preliminary and unaudited, and that final audited results will be disclosed in the annual report. The document is short (849 characters) and serves as an announcement of expected financial performance rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2022
2023-01-19 Chinese
关于使用募集资金继续增资全资子公司实施募投项目的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of raised funds to increase capital in a wholly-owned subsidiary, including details of board approval and registration changes. It references previous announcements and provides specific financial figures related to capital increase. The content focuses on financing activities and capital structure changes rather than a full financial report or earnings release. The document length is short and it is a formal announcement of a capital increase using raised funds, fitting the Capital/Financing Update category.
2023-01-12 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.